The arrival of biosimilars like Celltrion’s STEQEYMA and Biocon’s YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As competition intensifies, these biosimilars are reshaping treatment choices and driving a […]
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors, such as larotrectinib (VITRAKVI), may influence growth, its ability […]
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader approvals for early-stage treatment […]
A Germany-based mid-sized pharma company actively engaged in the late-stage development of a therapy for Primary Immunodeficiency (PID) and, with a strong marketing and drug commercialization presence in Europe, sought to assess the launch readiness […]
With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO’s market growth is driven by expanding indications and strategic partnerships. However, competition from KEYTRUDA and TECENTRIQ poses challenges, making differentiation through combination strategies key […]
